CAS MEDICAL SYSTEMS INC
Healthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $21.9M | $18.8M | $18.7M | $19.5M | $19.2M | $21.9M |
| Operating income | −$4.5M | −$6.4M | −$6.3M | −$6.6M | −$6.7M | −$10.5M |
| Net income | −$6.0M | −$2.3M | −$3.2M | −$6.9M | −$7.6M | −$10.4M |
| Total assets | $10.8M | $13.0M | $14.7M | $16.6M | $15.4M | $18.2M |
| Total liabilities | $13.1M | $10.5M | $11.3M | $10.9M | $12.3M | $8.7M |
| Equity | −$2.3M | $2.5M | $3.4M | $5.7M | $3.2M | $9.4M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 28.7M | 28.2M | 27.3M | 26.7M | 19.4M | 13.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- −20.5%
- Net margin
- −27.2%
- Return on equity
- 263.4%
- Return on assets
- −54.9%
- Return on capital (ROCE)
- −60.9%
- Liabilities / assets
- 120.9%
- Debt / equity
- —
- Book value / share
- $-0.08
- Revenue growth (YoY)
- 16.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- -15.01distress
- Accruals / assets
- −31.0%clean
- Beneish M-Score
- -3.94normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2009
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Thomas, Mcnerney &Amp; Partners Ii L.P.10% owner | Apr 18, 2019 | Conversion | 6.8M | $2.39 |
| Baird Jeffery AOfficer — Chief Financial Officer | Apr 18, 2019 | D | 304,418 | $2.45 |
| Gamelin JohnOfficer — Vice President, R&D | Apr 18, 2019 | D | 186,078 | $2.45 |
| Molloy Paul ADirector | Apr 18, 2019 | D | 42,500 | $2.45 |
| Milinazzo AlanDirector | Apr 18, 2019 | D | 42,500 | $2.45 |
| Patton Thomas MOfficer — President and CEO | Apr 18, 2019 | D | 930,889 | $2.45 |
| Thomas James EDirector | Apr 18, 2019 | D | 63,454 | $2.45 |
| Tune Kathleen ADirector | Apr 18, 2019 | D | 63,454 | $2.45 |
| Rainey Gregory PDirector | Apr 18, 2019 | D | 70,431 | $2.45 |
| Benni PaulOfficer — Chief Scientific Officer | Apr 18, 2019 | D | 177,379 | $2.45 |
| Weisshaar Kenneth RDirector | Apr 18, 2019 | D | 70,303 | $2.45 |
| Edwards Lifesciences Holding, Inc.10% owner | Apr 18, 2019 | J | 40.0M | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteApr 18, 2019
- Other material eventApr 9, 2019
- Entered a material agreement · Director / officer changeMar 12, 2019
- Entered a material agreement · Amended charter or bylaws · Other material eventFeb 12, 2019
- Results of operationsJan 3, 2019
- Results of operationsOct 31, 2018
- Results of operationsAug 2, 2018
- Shareholder voteJun 22, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GApr 29, 2019
- EFFECTApr 25, 2019
- EFFECTApr 25, 2019
- EFFECTApr 25, 2019
- EFFECTApr 25, 2019
- EFFECTApr 25, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
- 4PRIMARY DOCUMENTApr 22, 2019
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.